Ratio Therapeutics Enters License and Collaboration Agreement for  SSTR2-targeting Radiotherapeutic Candidate

Ratio Therapeutics Enters License and Collaboration Agreement for  SSTR2-targeting Radiotherapeutic Candidate

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.

WilmerHale advised Ratio Therapeutics Inc, a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, on its exclusive worldwide license and collaboration agreement for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer. Under the terms of the agreement, Ratio will receive combined upfront and potential milestone payments of up to $745M and is eligible to receive tiered royalty payments.

Sarah Hogan, Lauren Leonard and Jenna Ventorino represented Ratio on the transaction, with Stuart Falber and Rebecca Nauta advising on corporate matters, Fred Adam advising on tax matters, Bruce Manheim advising on FDA matters and Heather Petruzzi advising on IP matters.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel